Abstract
Hypoxic-ischemic brain damage (HIBD) remains a significant cause of neonatal mortality and long-term neurological impairment. Currently, therapeutic hypothermia is the only established clinical intervention. This study utilizes peptidome analysis of cerebrospinal fluid (CSF) to identify differentially expressed peptides that may serve as novel therapeutic targets. Using iTRAQ LC-MS/MS, 35 differentially expressed peptides were identified between HIBD neonates and controls. A specific fragment of heat shock protein 90-alpha (HSP90α), termed HIBDAP, was found to be down-regulated in HIBD. Functional assays revealed that HIBDAP exerts neuroprotective effects by suppressing the NLRP3-mediated pyroptosis pathway in neuronal cells subjected to oxygen-glucose deprivation (OGD). These findings highlight the potential of HIBDAP as a candidate for peptide-based neuroprotective therapy.
Introduction
Neonatal hypoxic-ischemic brain damage (HIBD) is a devastating condition resulting from systemic hypoxemia and reduced cerebral blood flow. It affects approximately 1 to 8 per 1,000 live births in developed countries and significantly more in resource-limited settings. Survivors often face lifelong challenges, including cerebral palsy, epilepsy, and cognitive deficits. While therapeutic hypothermia has improved outcomes, many infants still suffer significant injury, necessitating the search for pharmacological adjuncts.
Peptidomics, the comprehensive study of endogenous peptides, offers a unique window into the physiological state of the brain. Unlike proteins, peptides are often small, stable, and capable of crossing biological barriers, making them attractive both as biomarkers and therapeutic agents. This study aimed to characterize the CSF peptidome in HIBD neonates to identify fragments with potential neuroprotective properties.
Materials and Methods
Clinical Samples
Cerebrospinal fluid was collected from eight neonates: four diagnosed with HIBD and four healthy controls at the Children’s Hospital of Nanjing Medical University. Samples were processed to remove high-molecular-weight proteins and enriched for the peptide fraction.
Peptidomic Analysis
Peptides were labeled using isobaric tags for relative and absolute quantitation (iTRAQ) and analyzed via liquid chromatography-tandem mass spectrometry (LC-MS/MS). Data were searched against the SwissProt database to identify precursor proteins.
Bioinformatics and Functional Validation
Protein-protein interaction (PPI) networks were constructed using the STRING database, and pathway enrichment was performed via KEGG. A lead candidate peptide, HIBDAP, was synthesized with a TAT cell-penetrating peptide sequence (TAT-HIBDAP). Its effects were tested in PC12 cells subjected to oxygen-glucose deprivation (OGD) to simulate HIBD conditions. Cell viability was assessed via CCK-8 assays, and the expression of pyroptosis-related markers (NLRP3, ASC, Caspase-1) was measured using Western blotting.
Results
Identification of Differentially Expressed Peptides
The analysis identified 35 unique peptides derived from 25 precursor proteins that were differentially expressed in HIBD CSF. Notably, 34 of these 35 peptides were down-regulated in the HIBD group. Bioinformatics analysis identified a fragment of HSP90α (HSQFIGYPITLFVEKER), designated HIBDAP, as a central node in the PPI network associated with the NOD-like receptor (NLR) signaling pathway.
Characterization of HIBDAP
HIBDAP is a 17-amino acid hydrophilic peptide with high stability and a half-life of approximately 3.5 hours in mammalian reticulocytes. Confocal microscopy confirmed that TAT-HIBDAP successfully penetrated the cell membrane and localized within the nucleus of PC12 cells.
Neuroprotective Effects and Mechanism
In the OGD model, pretreatment with HIBDAP at low concentrations (e.g., 5 µM) significantly improved cell survival. However, a high concentration (40 µM) exhibited cytotoxicity. HIBDAP treatment led to a significant reduction in the expression of NLRP3, ASC, and Caspase-1, key components of the inflammasome that drive pyroptosis. Interestingly, HIBDAP did not affect NLRP1 expression, suggesting a specific inhibitory effect on the NLRP3 pathway.
Discussion
The predominance of down-regulated peptides in the CSF of HIBD neonates suggests that the loss of naturally occurring neuroprotective fragments may exacerbate brain injury. HIBDAP, derived from the molecular chaperone HSP90α, appears to play a critical role in modulating the inflammatory response. By inhibiting the NLRP3 inflammasome, HIBDAP prevents pyroptosis—a form of programmed cell death that releases pro-inflammatory cytokines and propagates tissue damage.
While these results are promising, the study is limited by a small clinical sample size and the reliance on an in vitro model. Future research should focus on validating these findings in larger cohorts and evaluating the efficacy and safety of HIBDAP in vivo using animal models of HIBD. The narrow therapeutic window observed also necessitates careful dose-response studies to optimize clinical potential.
Conclusion
This study provides a comprehensive profile of the CSF peptidome in neonatal HIBD and identifies HIBDAP as a novel neuroprotective candidate. By targeting the NLRP3-mediated inflammatory pathway, HIBDAP offers a potential new strategy for mitigating the devastating effects of neonatal brain injury.
Summary updated